These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 27615021)

  • 1. Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy.
    van Erning FN; Janssen-Heijnen ML; Creemers GJ; Pruijt JF; Maas HA; Lemmens VE
    Int J Cancer; 2017 Jan; 140(1):224-233. PubMed ID: 27615021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
    Pectasides D; Karavasilis V; Papaxoinis G; Gourgioti G; Makatsoris T; Raptou G; Vrettou E; Sgouros J; Samantas E; Basdanis G; Papakostas P; Bafaloukos D; Kotoula V; Kalofonos HP; Scopa CD; Pentheroudakis G; Fountzilas G
    BMC Cancer; 2015 May; 15():384. PubMed ID: 25956750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
    Sobrero A; Lonardi S; Rosati G; Di Bartolomeo M; Ronzoni M; Pella N; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Zagonel V; Maiello E; Barni S; Rulli E; Labianca R;
    J Clin Oncol; 2018 May; 36(15):1478-1485. PubMed ID: 29620994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study.
    Osawa H; Handa N; Minakata K
    Oncol Res; 2014; 22(5-6):325-31. PubMed ID: 26629945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged Capecitabine Chemotherapy Following Capecitabine and Oxaliplatin (CAPOX) Regimen Chemotherapy Failed to Improve Survival of Stage III Colorectal Cancer After Radical Resection.
    Xu JL; Tang CW; Feng WM; Bao Y; Chai ZZ
    Med Sci Monit; 2019 Jun; 25():4831-4836. PubMed ID: 31254462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer.
    Loree JM; Mulder KE; Ghosh S; Spratlin JL
    Clin Colorectal Cancer; 2014 Sep; 13(3):172-7. PubMed ID: 24630275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer.
    Arkenau HT; Graeven U; Kubicka S; Grothey A; Englisch-Fritz C; Kretzschmar A; Greil R; Freier W; Seufferlein T; Hinke A; Schmoll HJ; Schmiegel W; Porschen R;
    Clin Colorectal Cancer; 2008 Jan; 7(1):60-4. PubMed ID: 18279579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
    Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
    J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensity of adjuvant chemotherapy regimens and grade III-V toxicities among elderly stage III colon cancer patients.
    van Erning FN; Razenberg LG; Lemmens VE; Creemers GJ; Pruijt JF; Maas HA; Janssen-Heijnen ML
    Eur J Cancer; 2016 Jul; 61():1-10. PubMed ID: 27128782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
    Snoeren N; Voest EE; Bergman AM; Dalesio O; Verheul HM; Tollenaar RA; van der Sijp JR; Schouten SB; Rinkes IH; van Hillegersberg R
    BMC Cancer; 2010 Oct; 10():545. PubMed ID: 20937118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
    Porschen R; Arkenau HT; Kubicka S; Greil R; Seufferlein T; Freier W; Kretzschmar A; Graeven U; Grothey A; Hinke A; Schmiegel W; Schmoll HJ;
    J Clin Oncol; 2007 Sep; 25(27):4217-23. PubMed ID: 17548840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of capecitabine plus oxaliplatin (CapOX) as adjuvant chemotherapy for locally advanced rectal cancer (CORONA II).
    Hattori N; Nakayama G; Uehara K; Aiba T; Ishigure K; Sakamoto E; Tojima Y; Kanda M; Kobayashi D; Tanaka C; Yamada S; Koike M; Fujiwara M; Nagino M; Kodera Y
    Int J Clin Oncol; 2020 Jan; 25(1):118-125. PubMed ID: 31542847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
    Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
    J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extending chemotherapy with capecitabine following CAPOX chemotherapy improves survival of Stage 3 gastric carcinoma after radical surgery: a 5-year analysis.
    Fei Y; Huang SX; Fei MY; Pan XP
    Eur Rev Med Pharmacol Sci; 2020 Nov; 24(21):11344-11349. PubMed ID: 33215454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases.
    Satake H; Hashida H; Tanioka H; Miyake Y; Yoshioka S; Watanabe T; Matsuura M; Kyogoku T; Inukai M; Kotake T; Okita Y; Matsumoto T; Yasui H; Kotaka M; Kato T; Kaihara S; Tsuji A
    Oncologist; 2021 Jul; 26(7):e1125-e1132. PubMed ID: 33977607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients.
    Sun J; Ilich AI; Kim CA; Chu MP; Wong GG; Ghosh S; Danilak M; Mulder KE; Spratlin JL; Chambers CR; Sawyer MB
    Clin Colorectal Cancer; 2016 Sep; 15(3):257-63. PubMed ID: 26803708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.
    Souglakos J; Boukovinas I; Kakolyris S; Xynogalos S; Ziras N; Athanasiadis A; Androulakis N; Christopoulou A; Vaslamatzis M; Ardavanis A; Emmanouilides C; Bompolaki I; Kourousis C; Makrantonakis P; Christofyllakis C; Athanasiadis E; Kentepozidis N; Karampeazis A; Katopodi U; Anagnosopoulos A; Papadopoulos G; Prinarakis E; Kalisperi A; Mavroudis D; Georgoulias V
    Ann Oncol; 2019 Aug; 30(8):1304-1310. PubMed ID: 31228203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.